News stories about "experimental" in India.

Beam Therapeutics to cut 20% of workforce as part of restructuring plan

Beam Therapeutics (BEAM.O) said on Thursday it will focus on developing its experimental sickle cell disease treatments and reduce about 20% of its current workforce, or 100 employees, as part of a restructuring plan. Key Points

Reuters

AstraZeneca raises stakes in obesity drug race with Eccogene deal

AstraZeneca (AZN.L) moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an experimental oral drug in the field. Key Points

Reuters

Immunovant shares surge after antibody treatment succeeds in early-stage study

Shares of Immunovant (IMVT.O) surged over 60% in premarket trading on Tuesday, after data from an early-stage study showed the drug developer's experimental treatment helped reduce levels of an inflammation-causing antibody in healthy adults. Key Points

Reuters

An AI failure database can help foster innovation safety

Experimental technologies thrive on a 'culture of failure' as that’s how we learn from mistakes. We can mitigate AI risks by recording and analyzing mishaps. This is how aviation grew safer. Key Points

mint

Moderna, Merck begin late-stage study for mRNA cancer therapy

Moderna (MRNA.O) and Merck & Co (MRK.N) said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer. Key Points

Reuters

Merck's lung cancer drug combo fails to meet trial goal

Merck (MRK.N) said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study. Key Points

Reuters

Moderna's combination skin cancer therapy receives FDA's breakthrough tag

Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients. Key Points

Reuters